<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557908</url>
  </required_header>
  <id_info>
    <org_study_id>VWD PN</org_study_id>
    <nct_id>NCT00557908</nct_id>
  </id_info>
  <brief_title>The Von Willebrand Disease (VWD) International Prophylaxis Study</brief_title>
  <acronym>VIP</acronym>
  <official_title>The VWD International Prophylaxis (VIP) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood Center of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The von Willebrand Disease Prophylaxis Network (VWD PN) is an international study group
      formed with the goal of investigating the role of prophylaxis in clinically severe VWD that
      is non-responsive to other treatment(s).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common indications for vWD prophylaxis included joint bleeding, epistaxis,
      gastrointestinal (GI) bleeding, and menorrhagia. Thus, an effort to establish optimal
      treatment regimens for these indications, through a period of prospective evaluation, is the
      primary focus of this research. Other goals include a retrospective study of the effect of
      prophylaxis on bleeding frequency, and a retrospective natural history study of GI bleeding
      in VWD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>von Willebrand Disease associated bleeding frequency</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal treatment regimens for joint bleeding, GI bleeding, epistaxis, and menorrhagia</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>VWF/FVIII product infusions</arm_group_label>
    <description>One to three infusions of factor replacement as needed to control bleeding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VWF/FVIII products</intervention_name>
    <description>Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)
Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.
Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses</description>
    <arm_group_label>VWF/FVIII product infusions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The VWD population includes those with Type 1 if &lt;/=20% RCo and/or &lt;/=20% FVIII; and DDAVP
        non-responsive; Type 2 if DDAVP non-responsive, or Type 2B; and Type 3; who meet bleeding
        indication criteria having defined patterns of gastrointestinal bleeding, joint bleeding,
        epistaxis, or menorrhagia.

        Individuals already on prophylaxis for VWD, for any indication, and individuals who were on
        a regimen of prophylaxis for at least six months that was discontinued because it was no
        longer required, or those with a history of GI bleeding due either to proven angiodysplasia
        or unexplained by other factors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 1: eligible for participation if

          -  ≤20% RCo and/or ≤20% FVIII; and

          -  DDAVP non-responsive, defined as occurrence of bleeding episodes not responding
             satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator;
             and

          -  Bleeding indication criteria are met

        Type 2: eligible for participation if

          -  DDAVP non-responsive, defined as occurrence of bleeding episodes not responding
             satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator;
             or Type 2B;

          -  Bleeding indication criteria are met

        Type 3: eligible for participation if

          -  Bleeding indication criteria are met

        Bleeding Indication Criteria:

          -  Joint Bleeding: documentation of at least two apparently spontaneous bleeding episodes
             in the same joint in the six months prior to enrollment; or three or more apparently
             spontaneous bleeding episodes in different joints in the six months prior to
             enrollment.

          -  GI Bleeding: history of two or more severe GI bleeding episodes associated with either
             a drop in hemoglobin of ≥ 2 g/dl or requiring red blood cell transfusion or treatment
             with VWD concentrate.

          -  Failure to identify other causes of bleeding.

          -  Menorrhagia: a diagnosis of menorrhagia; prospectively completed Pictorial Blood
             Assessment Chart score &gt;185 or required treatment with a VWD product for menstrual
             bleeding on one or more occasions in the year prior to enrollment.

          -  Normal cervical cytology (PAP) within the six months prior to enrollment for females ≥
             18 years of age.

          -  Epistaxis 1. Three or more bleeding episodes in a six-month period that required
             treatment with VWD concentrates or red cell transfusions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Berntorp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skåne University Hospital, Malmö, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Abshire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Center of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rho, Inc.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BloodCenter of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201-2178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>SE-20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8. doi: 10.1097/MBC.0000000000000257.</citation>
    <PMID>25688461</PMID>
  </results_reference>
  <results_reference>
    <citation>Makris M, Federici AB, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2015 May;21(3):338-42. doi: 10.1111/hae.12571. Epub 2014 Nov 7.</citation>
    <PMID>25381842</PMID>
  </results_reference>
  <results_reference>
    <citation>Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E; VWD PN. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013 Jan;19(1):76-81. doi: 10.1111/j.1365-2516.2012.02916.x. Epub 2012 Jul 23.</citation>
    <PMID>22823000</PMID>
  </results_reference>
  <results_reference>
    <citation>Berntorp E, Abshire T; von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost. 2006 Nov;4(11):2511-2.</citation>
    <PMID>17059476</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Sharyne M. Donfield, Ph.D.</investigator_full_name>
    <investigator_title>Principal Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Von Willebrand Disease</keyword>
  <keyword>VWD</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

